ORUM

Orum Therapeutics, Inc. is a biopharmaceutical company engaged in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. Its pipeline includes ORM-6151, in Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, in pre-clinical trials for acute myeloid leukemia and hematologic malignancies; and ORM-1023, in pre-clinical trials for small cell lung cancer and neuroendocrine tumors. The company is also developing programs for solid tumors, immunology and inflammation, and an E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. Founded in 2016, Orum Therapeutics is headquartered in Daejeon, South Korea.